Roche CEO not ruling out orphan drug entrance

In Clinical Development by Tim Peplow

roche orphan rare disease (wikimedia: andrew wales)

It’s not so much what Roche CEO Severin Schwan said, it’s more what he didn’t say.

According to Reuters, Schwan told reporters at a Paris news conference that Swiss company based its focus not on the size of patient population but on how much additional value and medical benefit could be generated for individual patients. “We go where the science takes us, wherever it is, independent from the size of the patient population,” Schwan said.

Speculators will be hanging on to those last few words from Schwan. ‘Independent from the size of the patient population.’ In effect, Schwan hasn’t ruled out a move into rare diseases – but neither has he specifically ruled it in. He gave no comment about the rumoured Alexion or BioMarin takeover bids – rumours that have been rumbling for the past few months.

Read the article from Reuters >

Join our discussion on LinkedIn, or leave a comment below. Want more from Total Orphan Drugs? Sign up to our newsletter – it doesn’t cost anything and only takes a minute.

Download the brochure for the World Orphan Drug Congress Europe 2013, 14-15 November 2013, Geneva.